Back to search
Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced Resectable Oral Cavity Squamous Cell Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced Resectable Oral Cavity Squamous Cell Cancer trials you may qualify forThe dosing regimen in the trial group was: tirilizumab with albumin-bound paclitaxel and cisplatin for 3 preoperative Cycles. After neoadjuvant therapy, patient…
The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up…
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and th…
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patie…
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropha…
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the c…